Cabergoline monotherapy in polycystic ovary syndrome patients with elevated prolactin: a viable option?

Basit Öğe Kaydı
dc.authorid0009-0001-7684-0319
dc.authorid0000-0003-3590-2656
dc.authorid0000-0003-0022-5704
dc.authorid0000-0002-4957-9856
dc.contributor.authorSiginir, Asli
dc.contributor.authorBostan, Hayri
dc.contributor.authorSaygili, Emre Sedar
dc.contributor.authorTufan, Ceren
dc.contributor.authorKarakilic, Ersen
dc.date.accessioned2026-02-03T12:02:58Z
dc.date.available2026-02-03T12:02:58Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose Cabergoline is widely used to treat hyperprolactinemia, but its effects on polycystic ovary syndrome (PCOS) remain unclear. Since hyperprolactinemia is present in nearly 30% of PCOS cases, this study aims to assess the impact of cabergoline on androgen levels and clinical outcomes in PCOS with elevated prolactin cases, discussing these findings with the results in prolactinoma cases. Methods A total of 66 women aged 18-40 were included in this retrospective cohort study, with 36 in the PCOS with elevated prolactin group (median 24.0 (22.0-27.5) years) and 30 in the prolactinoma group (median 28.0 (23.7-33.0) years). Only patients who had been started on cabergoline treatment and had available follow-up data were included. Hormonal profiles and clinical findings, including hirsutism, and menstrual cycle regularity, were assessed before and after cabergoline treatment. Results After cabergoline treatment, significant reductions in prolactin and total testosterone levels were observed in both groups. In the PCOS group, total testosterone decreased from 0.65-0.49 ng/mL (p < 0.001) and dehydroepiandrosterone-sulphate levels from 407.5-301.0 g/dL (p < 0.001). In the prolactinoma group, total testosterone decreased from 0.39-0.29 ng/mL (p < 0.001). Menstrual irregularities improved markedly in both groups, with prevalence decreasing from 83.3-5.6% in PCOS group and from 80.0-10.0% in the prolactinoma group (p < 0.001). Furthermore, in PCOS group, the prevalence of hirsutism was decreased from 86.1-61.1% (p = 0.007). Conclusion Cabergoline is effective in lowering prolactin and androgen levels while improving menstrual regularity in both PCOS and prolactinoma patients, highlighting its potential as a valuable therapeutic option for patients with PCOS with elevated prolactin.
dc.description.sponsorshipScientific and Technological Research Council of Turkiye (TUBIdot;TAK)
dc.description.sponsorshipOpen access funding provided by the Scientific and Technological Research Council of Turkiye (TUB & Idot;TAK).
dc.identifier.doi10.1007/s12020-025-04279-8
dc.identifier.endpage555
dc.identifier.issn1355-008X
dc.identifier.issn1559-0100
dc.identifier.issue2
dc.identifier.pmid40399716
dc.identifier.scopus2-s2.0-105005591956
dc.identifier.scopusqualityQ2
dc.identifier.startpage547
dc.identifier.urihttps://doi.org/10.1007/s12020-025-04279-8
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34908
dc.identifier.volume89
dc.identifier.wosWOS:001492404800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofEndocrine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260130
dc.subjectCabergoline
dc.subjectPolycystic ovary syndrome
dc.subjectProlactinoma
dc.subjectAndrogens
dc.subjectMenstrual irregularities
dc.subjectHirsutism
dc.titleCabergoline monotherapy in polycystic ovary syndrome patients with elevated prolactin: a viable option?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu